This is in accordance with our previous data that HEL cells hardly undergo apoptosis by inhibition of JAK2-V617F alone [5], which may partly explain the limited efficacy of ruxolitinib in eradicating the JAK2-V617F clone in both MPNs and post-MPN secondary AML [8,9,10]. The gene discussed is JAK2; the disease is acute myeloid leukemia.